Ongoing developments in microbiome science are opening up new frontiers for probiotic and prebiotic research and producers. The ability to communicate about probiotics and prebiotics to key stakeholders is heavily influenced by the regulatory environment while European regulation has already rejected many health claims. How do innovative players handle the regulatory constraints and moving landscape? What are the opportunities to get the claims right and make them scientifically valid? What are the recent changes in regulation?